Whole Exome Sequencing of iMCD patients

Join the drive to collect 300 samples for life-saving research in 2020!

One of CSTL's partners, the Castleman Disease Collaborative Network (CDCN), is collaborating with the Broad Institute at Harvard and MIT to perform a large sequencing study of blood from 300 HHV-8-negative/idiopathic multicentric Castleman disease (iMCD) patients. The CDCN needs every iMCD patient to help by contributing a blood sample and donating medical records to the ACCELERATE registry. All 300 iMCD patient samples must be submitted to the Broad Institute for sequencing by Fall 2020.

We have made it as easy as possible for you to help. The CDCN will send patients a kit in the mail that they can take to a nearby Quest Diagnostics lab for the blood draw or to their next scheduled phlebotomy visit. All costs are automatically covered for anything involved in sample collection.

If you are a physician/researcher, please let your patients know about this important study and direct them to the CDCN website: https://cdcn.org/our-cure/. Patients who have iMCD and are interested in contributing a blood sample to research can directly contact our Center Coordinator, Johnson Khor, via email, phone, or text to: castlebank@uphs.upenn.edu or 267-586-9977.